Hoogenraad - Development of therapeutic antibodies against cachexia

Group leader

Nicholas HoogenraadProfessor Nicholas Hoogenraad

Emeritus Professor AO, College of Science, Health and Engineering

View profile, publications and contact details

Research overview

We have discovered a receptor that causes cancer cachexia a complication of cancer that affects up to 80% of patients with solid tumours and is responsible for around 25% of cancer deaths. We have produced monoclonal antibodies that block this condition, giving the prospect of a treatment. The signal for cachexia originates in the tumor leading to a search for the soluble factor released into the blood stream. We are in the process of humanizing the antibody in preparation for clinical trials.

Research area